Bionano Genomics BNGO 深 沪
等待开盘 09-23 09:30:00 美东时间
1.771
-0.019
-1.06%
华盛通- 最 高1.83
- 今 开1.79
- 成交量 107.80万股
- 最 低 1.70
- 昨 收 1.79
- 总市值 829.01万
- 52周最高 28.80
- 市盈率 静 --
- 换手率 23.03%
- 52周最低 1.50
- 委 比 36.41%
- 总股本 468.10万
- 历史最高 9414.00
- 量 比 0.64
- 振 幅 7.26%
- 历史最低 1.70
- 每 手 1
- 风险率 7.05%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Why BioNano Genomics (BNGO) Stock Is Getting Hammered Tuesday
BioNano Genomics shares are trading sharply lower in Tuesday's session. The company announced the pricing of a $10 million public offering.
09-17 00:53
Bionano Genomics slides after pricing $10M equity offering
Bionano Genomics (NASDAQ:BNGO) has priced a public offering of 5M shares of its common stock (or equivalents) with accompanying Series E and short-term Series F warrants, at a combined public offering...
09-16 21:28
Bionano Genomics, Inc. Announces Pricing of $10 Million Public Offering
Bionano Genomics announced a public offering of 5 million shares of common stock and accompanying Series Warrants, priced at $2.00 per share. The Series E warrants expire in five years, while the short-term Series F warrants expire in 18 months. The company expects gross proceeds of approximately $10 million, with potential additional proceeds of $20 million if the warrants are fully exercised. H.C. Wainwright & Co. is the placement agent. Procee...
09-16 13:10
Multiple Studies Highlighting OGM Utility For Analysis of Cancer Biomarker Chromoanagenesis Published in Dedicated Issue of Methods in Molecular Biology
Bionano Genomics announced the publication of a book seriesvolume dedicated to chromoanagenesis, a catastrophic genome rearrangement linked to cancer. Optical genome mapping (OGM) is highlighted as a powerful tool for detecting and analyzing complex chromoanagenesis events, offering a genome-wide, high-resolution view of structural variants that traditional methods struggle to address. The volume includes studies on acute myelogenous leukemia (AM...
09-16 11:00
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Check-Cap (NASDAQ:CHEK) shares rose 225.1% to $2.42 during Monday's re...
09-16 01:06
CMS Posts Preliminary Payment Determination for New Category I CPT Code Covering Use of OGM for Constitutional Genetic Disorders
Bionano Laboratories announced that CMS approved a new Category I CPT code (81354) for optical genome mapping (OGM) in detecting structural variations related to constitutional genetic disorders. Priced at $1263.53, the code is higher than existing microarray codes (81228: $900 and 81229: $1160). This follows the approval of code 81195 for hematologic malignancies. Bionano offers OGM-Dx Postnatal and Prenatal Whole Genome SV tests, expected to be...
09-15 11:00
Bionano Genomics Selected For Sole Source Contract By NIH For Optical Genome Mapping Reagents And Instruments; No Contract Value Disclosed
https://sam.gov/opp/7a19a6e8954c4de1a128b841e2018400/view DescriptionThis is a notice of intent, not a request for a quotation. A solicitation document will not be issued and quotations will not be requested.This
09-02 23:43
Bionano to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Bionano Genomics, Inc. announced that its CEO, Erik Holmlin, will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 8, 2025, at 3:00 p.m. ET. The presentation will be available via webcast and replay through Bionano's website for 30 days.
08-25 12:00
HC Wainwright & Co. Maintains Buy on Bionano Genomics, Raises Price Target to $11
HC Wainwright & Co. analyst Yi Chen maintains Bionano Genomics (NASDAQ:BNGO) with a Buy and raises the price target from $10 to $11.
08-18 19:27
Bionano Genomics Q2 EPS $(1.99) Beats $(2.42) Estimate, Sales $6.733M Miss $6.832M Estimate
Bionano Genomics (NASDAQ:BNGO) reported quarterly losses of $(1.99) per share which beat the analyst consensus estimate of $(2.42) by 17.6 percent. This is a 86.18 percent increase over losses of $(14.40) per share from
08-15 04:34
